A small molecule with larger-than-expected effects on hepatitis B virus.

Area of Science:

• Hepatology
• Virology
• Immunology

Background:

• Chronic hepatitis B virus (HBV) infection impacts approximately 250 million individuals globally.
• Achieving a functional cure for chronic HBV remains a significant clinical challenge with current therapies.

Purpose of the Study:

• To evaluate the efficacy of the capsid assembly modulator GLP-26 in a novel preclinical model of chronic HBV infection.
• To assess the impact of GLP-26 on viral markers and host immune responses.

Main Methods:

• Development of a double-humanized chronic HBV murine model.
• Administration of the capsid assembly modulator GLP-26 to the HBV-infected mice.
• Quantification of HBV DNA and surface antigen levels, and assessment of immunomodulatory effects.

Main Results:

• GLP-26 treatment led to a significant reduction in circulating HBV DNA.
• Treatment with GLP-26 decreased HBV surface antigen levels in the blood.
• The drug demonstrated immunomodulatory properties in the chronic HBV model.

Conclusions:

• GLP-26 is a promising therapeutic candidate for chronic HBV infection.
• The developed humanized mouse model is valuable for testing novel HBV therapeutics.
• GLP-26 warrants further investigation for its potential to achieve a functional cure in HBV patients.